VectivBio AG
Edit

VectivBio AG

https://vectivbio.com/
Last activity: 30.10.2023
Categories: LivingLEDITProductMedTechBusinessBuildingBioTechInterestDevelopment
VectivBio AG is a clinical-stage biotechnology company focused on rare diseases with a well-defined biology that can be targeted with transformational therapeutics. VectivBio was formed in 2019 as a spinout from Therachon, a biotechnology company acquired by Pfizer, Inc., for its program in achondroplasia, with the ambition to continue to have an impact on people’s lives by bringing transformational medicines to patients with serious rare conditions. The company is led by a world-class leadership team with deep expertise in rare diseases and a track record of success in R&D, commercialization and business development for innovative products targeting orphan conditions with major unmet medical need. The company is drawing on the expertise of its founders as it continues to build a portfolio of rare disease medicines while advancing its lead program for Short Bowel Syndrome.
Mentions
36
Location: Switzerland, Basel-City, Basel
Employees: 11-50
Total raised: $324M
Founded date: 2019
Facebook
LinkedIn

Investors 3

Funding Rounds 4

DateSeriesAmountInvestors
20.10.2022-$125M-
29.06.2022-$54MForbion
15.10.2020-$110M-
07.01.2020-$35M-

Mentions in press and media 36

DateTitleDescriptionSource
30.10.2023Entrepreneur of the Year Award für Urban Connect und VectivB... Mit dem EY Entrepreneur Of The Year Award 2023 hat das Prüfungs- und Beratungsunternehmen EY in de...startuptic...
08.09.2023Startups und Scaleups im Finale des EY Entrepreneur Of The Y... Die unabhängige Jury hat entschieden, wer am 27. Oktober beim EY Entrepreneur Of The Year 2023 im ...startuptic...
23.05.2023Ironwood Pharma to acquire VectivBio for more than USD 1 bil... VectivBio is a clinical-stage biotechnology company focused on the discovery and development of tr...startuptic...
16.03.2023VectivBio and its partner conduct Japan-centric clinical tri... Based in Basel, VectivBio is a clinical-stage biopharmaceutical company pioneering novel transform...startuptic...
20.10.2022VectivBio raises $125 million VectivBio is focussed on therapies for severe rare conditions. Lead product candidate apraglutide ...startuptic...
13.10.2022VectivBio Announces Pricing of $125 Million Underwritten Off...BASEL, Switzerland, Oct. 13, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VE...forbion.co...
13.10.2022VectivBio Announces Pricing of $125 Million Underwritten Off...-tcgcrossov...
13.10.2022VectivBio Announces Pricing of $125 Million Underwritten Off...-orbimed.co...
05.07.2022VectivBio Announces Closing of $54 Million Aggregate Financi... VectivBio is a global clinical-stage biotechnology company focused on transforming and improving t...startuptic...
29.06.2022VectivBio Announces Closing of $54 Million Aggregate Financi...BASEL, Switzerland, June 29, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VE...globenewsw...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In